04:14 AM EDT, 04/17/2026 (MT Newswires) -- Kailera Therapeutics (KLRA) said late Thursday it priced its initial public offering of about 39.1 million common shares at $16 apiece for roughly $625 million in expected gross proceeds.

The obesity-focused biotechnology company said IPO underwriters have a 30-day overallotment option to purchase up to 5.9 million additional shares.

Kailera expects its shares to start trading on the Nasdaq Global Select Market under the KLRA ticker Friday, while the IPO is expected to close Monday.